Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. (Nevada) filed this Form 8-K on August 25, 2016, reporting a significant corporate development involving its wholly owned subsidiary, Creative Medical Technologies, Inc. ("CMT").
Key Financial Metrics
This filing is a Current Report (Item 8.01) and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The primary material change is the execution of a License Agreement between CMT and The Regents of The University of California (UC San Diego) on August 25, 2016. Key terms include:
- Exclusivity: CMT received exclusive rights to develop and commercialize therapeutics for inflammatory, degenerative, and immunological diseases, as well as cellular banking.
- Intellectual Property: The agreement covers US Patent No. 7,569,385 regarding multipotent amniotic fetal stem cells derived from amniotic fluid.
- Financial Obligations: CMT must pay an initial license fee within 30 days, annual maintenance fees (creditable toward royalties), milestone payments, and royalties on net sales. CMT must also reimburse the University for patent maintenance costs.
- Operational Requirements: CMT is obligated to diligently develop, manufacture, and sell licensed products and maintain adequate general liability insurance.
Outlook, Risks, and Management Commentary
Management explicitly stated that they have not yet determined the extent to which they intend to explore the use of the technology evidenced by the Patent. The agreement includes termination clauses allowing CMT to exit with 90 days' written notice, while the University may terminate if CMT fails to meet obligations (subject to a 30-day cure period). CMT is also required to indemnify the University against claims arising from the license exercise.
Investor Verification Checklist
- Verify the amount of the initial license fee and the schedule for annual maintenance fees.
- Confirm the specific milestone payment triggers and royalty percentages defined in the full agreement.
- Assess CMT's current cash position to determine if it can fund the initial fee and future diligence obligations.
- Review the status of US Patent No. 7,569,385 to ensure it is active and enforceable.
- Monitor future filings for updates on the strategic decision regarding the exploration of this technology.